BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

Impact · against what's priced in

BioVie (BIVI) sees a positive catalyst as Phase 2 subgroup data provides a clear path to optimize Phase 3 trial design for bezisterim in Long COVID. Kodal Minerals (KOD) receives marginal positive visibility regarding its exploration expansion into Ghana.

BIVI+0.60: No priced-in read yet
In context: Statistically significant improvements in fatigue (8.93 vs 5.30 points) and cognitive symptoms among severe subgroups provide a specific patient profile for Phase 3 optimization.
Read from the article alone

BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

KODNew
biotech▲19%
healthcare
BIVI
clinical trials
fda
long covid
pharma

BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

What matters in this story

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

What matters in this story

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

How each ticker is affected

Track these names every morning.

Gilead's pill succeeds in mid-stage bowel disease trial

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

GSK lung cancer drug shows 61% response rate in early global trial

BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

What matters in this story

Next reads from the same story arc

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups

What matters in this story

Next reads from the same story arc

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

How each ticker is affected

Track these names every morning.

Gilead's pill succeeds in mid-stage bowel disease trial

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

GSK lung cancer drug shows 61% response rate in early global trial